Wells Fargo downgraded Regulus (RGLS) to Equal Weight from Overweight with a price target of $9, up from $6, after the company agreed to be acquired by Novartis (NVS) for $7 per share in cash and a $7 per share contingent value right.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGLS: